State Food and Drug Administration
In October 2010, the Indian Company Cipla launched the drug as "Pirfenex", and MSN laboratories launched it as "Pulmofib". It was approved for use in Europe in 2011 under the trade name "Esbriet"; it was approved in Canada in 2012 under the same name; and was approved in the United States in October 2014, also as "Esbriet". In September 2011, the Chinese State Food and Drug Administration provided GNI Group Ltd with new drug approval of pirfenidone in China, and later manufacture approval in 2013 under the trade name of "Etuary".